The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
分析師眼中的再生元製藥公司：14種不同觀點
Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Regeneron Pharmaceuticals (NASDAQ:REGN) in the last three months.
在過去三個月中，有14位分析師公佈了Regeneron Pharmicals（納斯達克股票代碼：REGN）的評級，提供了從看漲到看跌的不同視角。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他們最近的評級，簡要介紹了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Regeneron Pharmaceuticals, presenting an average target of $1111.86, a high estimate of $1229.00, and a low estimate of $925.00. This current average reflects an increase of 2.09% from the previous average price target of $1089.08.
在評估12個月目標股價時，分析師公佈了對Regeneron Pharmicals的見解，將平均目標股價定爲1111.86美元，最高估計爲1229.00美元，低估值爲925.00美元。目前的平均價格比之前的平均目標股價1089.08美元增長了2.09％。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
A comprehensive examination of...
對金融專...
登入免費觀看全文
登入/註冊